Evaluation of Cognitive functions and quality of life in epileptic patients: A Prospective Cross sectional Study

Background: Epilepsy is a chronic neurological disorder often impairing cognitive capacity and QoL. AEDs play a key role in seizure management, but the long-term implications for cognitive health and QoL vary with the type of AED used. To assess and compare cognitive function and QoL in patient populations treated for epilepsy with Phenytoin, Levetiracetam, Lacosamide, or Carbamazepine and to see whether a correlation exists between these two parameters Methods: This study was an 80-patient-based prospective cross-sectional one, in which participants were equally divided into four groups, each in course of AED monotherapy. The Montreal Cognitive Assessment (MoCA) scale was used to assess cognitive function, whereas QoL was assessed via the QOLIE-31 questionnaire. Data analysis was carried out by means of ANOVA, and Pearson correlation. Results: The mean MoCA score in the Phenytoin group was 23.5 ± 3.77, and in the Lacosamide group, 24.95 ± 3.51, whereas the mean QOLIE-31 score was observed to vary from 64.52 ± 13.84 to 68.40 ± 12.84. There were no statistically significant differences among the groups (p > 0.05). Strong positive correlations between MoCA and QOLIE-31 scores were observed within every group (from 0.9872 to 0.9935, p < 0.05). Conclusion: Regardless of whichever of the four AED groups was compared, cognitive and QoL scores did not differ from one another. Preserving cognition in Epilepsy is integral for improving overall well-being